Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma
Pancreatology · 2023
DOI: 10.1016/j.pan.2023.10.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pancreatology, 2023. Verfasst von Taichi Terai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Although the overall survival rate of patients with resectable pancreatic cancer has gradually improved, some patients relapse early and have a poor prognosis. This study aimed to identify the preoperative risk factors for early recurrence after neoadjuvant chemoradiotherapy in patients with resectable pancreatic cancer. METHODS: This study analyzed patients who underwent pancreatectomy after receiving neoadjuvant chemoradiotherapy for resectable pancreatic cancer between January 2009 and June 2021 and excluded those with borderline resectable and unresectable pancreatic cancers. Early recurrence was defined as recurrence within 6 months after surgery. RESULTS: This study included 203 patients, of whom 22 experienced early recurrence. The median survival time of patients with early recurrence was 18.3 months, which was significantly worse than that of patients with late recurrence (44.0 months, p 100 units/mL and a T status of ≥T2 after neoadjuvant chemoradiotherapy were independent predictive risk factors for early recurrence. The median recurrence-free survival time of patients with two risk factors was 9.7 months and significantly worse than that of those with either risk factors (20.5 months, p = 0.024) and those with no risk factor (26.2 months, p < 0.001). CONCLUSIONS: A combination of a high-level carbohydrate antigen 19-9 and a T status of ≥T2 after neoadjuvant chemoradiotherapy are predictors of early recurrence and may be helpful for selecting patients who require a stronger preoperative treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan.
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522, Japan. Electronic address: m-sho@naramed-u.ac.jp.
Zitieren
APA
Terai, T., Nagai, M., Nakamura, K., Kohara, Y., Yasuda, S., Matsuo, Y., Doi, S., Sakata, T., & Sho, M. (2023). Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma. Pancreatology. https://doi.org/10.1016/j.pan.2023.10.014
Vancouver
Terai T, Nagai M, Nakamura K, Kohara Y, Yasuda S, Matsuo Y, et al. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma. Pancreatology. 2023. doi:10.1016/j.pan.2023.10.014
BibTeX
@article{Terai2023,
author = {Terai, Taichi and Nagai, Minako and Nakamura, Kota and Kohara, Yuichiro and Yasuda, Satoshi and Matsuo, Yasuko and Doi, Shunsuke and Sakata, Takeshi and Sho, Masayuki},
title = {Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma},
journal = {Pancreatology},
year = {2023},
doi = {10.1016/j.pan.2023.10.014}
}
EUVIMED